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Molecular targeted therapies for pancreatic cancer: let’s stay in  
the hunt
The world is abuzz over the promise of molecular targeted therapies (MTTs) for cancer. As scientists 
reveal the molecular mechanics of cancer, from cell signaling to genomics to metabolomics, funding 
agencies deepen investments in discovery, ‘Pharma’ launches new expensive drugs and patients await with 
hope. Indeed, for some cancers, MTTs have fundamentally changed treatment strategies and improved 
clinical outcomes. Are MTTs perhaps the breakthrough so desperately needed for pancreatic cancer? 
Eltawil et al. from Nova Scotia provide the results of a systematic review and meta-analysis of selected 
randomized controlled trials (RCTs) evaluating the addition of variable MTTs to standard gemcitabine 
(G) for advanced pancreatic cancer. From 61 potentially relevant trials now published, the authors identi-
fied seven Phase III RCTs which collectively compared 1981 patients receiving G/molecular targeted 
agents (MTAs) to 1992 patients receiving G +/− placebo. They primarily assessed overall survival (OS) 
and secondarily assessed progression-free survival (PFS), overall response rates (ORRs) and advanced 
grade toxicities. The addition of MTAs to G indeed improved both PFS and ORRs, but these benefits 
were meager and offset by significantly higher treatment toxicities. Unfortunately, MTTs provided no 
extension in OS. These are, yet again, sobering but typical results for pancreatic cancer. The answer to 
this disease lies in its biology and not whether it can be safely removed. We must stay in this hunt for 
our new breakthrough therapy. Before long, we should refine, test and utilize MTTs according to molecu-
lar signatures determined and personalized to individual pancreatic cancer patients. Perhaps results will 
improve.
Mark Callery
Reducing blood loss in hepatic resection: not just the  
surgeon’s responsibility
The importance of the anesthetist to surgical outcomes is often under appreciated in published studies 
but not by a surgeon at an individual level. In this issue of HPB, McNally et al. have elegantly shown the 
importance of the anesthetist in contributing to surgical outcomes in hepatic surgery. In this two year 
retrospective study, 159 patients undergoing hepatic resection were reviewed. The key findings of this 
study showed that there was a weak relationship between peak central venous pressure and blood loss. 
In addition, increased blood loss correlated with an increased risk of complication. However, the novel 
finding and one that needs further study was that there was considerable variation in the use of intra-
operative fluids and trigger points for blood transfusion between anesthetists. As this study acknowledged, 
there are limitations on the interpretation of these data due to its retrospective nature. However, it does 
suggest that the standardization of the anesthetic for patients undergoing hepatic surgery in any depart-
ment would be important. It will remain mission critical for the whole team to be aware of ongoing blood 
loss so that as it reaches dedicated alert levels, intra-operative (such as placement of inflow control) and 
anesthetic modifications may need to be instituted to minimize ongoing losses. It would also seem logical 
that this be part of the time-out discussion or ‘surgical pause’, actively recognizing the patient being at 
risk of increased losses to allow the team to be forewarned.
Saxon Connor
Portal vein invasion in HCC – resection still possible
The propensity of hepatocellular carcinoma (HCC) to invade the portal vein is usually a marker of 
advanced disease and poor prognosis. Many HPB surgeons are reluctant to treat such HCC patients 
because of anticipated poor results in what is often difficult surgery. The study from Matono and colleagues 
reports outcomes from 29 patients with HCC and main portal vein invasion with a median survival of 
16.9 months and five year survival of 17%. At first glance, these figures may seem quite poor but compared 
with similar series they are actually very respectable. Importantly, these data suggest that there are some 
patients with advanced HCC who may still benefit from surgery. However, picking exactly which patients 
will benefit is difficult. Serum des-γ- carboxy prothrombin level (DCP) and clear margins at the time of 
surgery seem to be associated with a positive outcome from surgical resection. DCP is interesting because 
it appears to correlate with histological evidence of microvascular invasion as shown in other settings 
such as liver transplantation. Understanding the biology of these tumours through biomarkers or sur-
rogates for biological behaviour is clearly the key to understanding which patient will benefit from surgi-
cal excision. In addition, such data may also inform chemotherapeutic or biological strategies that might 
be used in combination with surgery.
Stephen J Wigmore
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